Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel

Jann N Sarkaria, Lin Yang, Patrick T. Grogan, Gaspar J. Kitange, Brett L. Carlson, Mark A. Schroeder, Evanthia Galanis, Caterina Giannini, Wenting Wu, Eduard B. Dinca, C. David James

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

In the current study, we examined a panel of serially passaged glioblastoma xenografts, in the context of an intracranial tumor therapy response model, to identify associations between glioblastoma molecular characteristics and tumor sensitivity to the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib. From an initial evaluation of 11 distinct glioblastoma xenografts, two erlotinib-sensitive tumors were identified, each having amplified EGFR and expressing wild-type PTEN. One of these tumors expressed truncated EGFRvIII, whereas the other expressed full-length EGFR. Subsequent cDNA sequence analysis revealed the latter tumor as expressing an EGFR sequence variant with arginine, rather than leucine, at amino acid position 62; this was the only EGFR sequence variant identified among the 11 xenografts, other than the aforementioned vIII sequence variant. EGFR cDNAs were then examined from 12 more xenografts to determine whether additional missense sequence alterations were evident, and this analysis revealed one such case, expressing threonine, rather than alanine, at amino acid position 289 of the extracellular domain. This glioblastoma was also amplified for EGFR, but did not display significant erlotinib sensitivity, presumably due to its lacking PTEN expression. In total, our study identified two erlotinib-sensitive glioblastoma xenografts, with the common molecular characteristics shared by each being the expression of wild-type PTEN in combination with the expression of amplified and aberrant EGFR.

Original languageEnglish (US)
Pages (from-to)1167-1174
Number of pages8
JournalMolecular Cancer Therapeutics
Volume6
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Glioblastoma
Epidermal Growth Factor Receptor
Heterografts
Neoplasms
Complementary DNA
Amino Acids
Threonine
Leucine
Alanine
Sequence Analysis
Arginine
Erlotinib Hydrochloride

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. / Sarkaria, Jann N; Yang, Lin; Grogan, Patrick T.; Kitange, Gaspar J.; Carlson, Brett L.; Schroeder, Mark A.; Galanis, Evanthia; Giannini, Caterina; Wu, Wenting; Dinca, Eduard B.; James, C. David.

In: Molecular Cancer Therapeutics, Vol. 6, No. 3, 03.2007, p. 1167-1174.

Research output: Contribution to journalArticle

Sarkaria, Jann N ; Yang, Lin ; Grogan, Patrick T. ; Kitange, Gaspar J. ; Carlson, Brett L. ; Schroeder, Mark A. ; Galanis, Evanthia ; Giannini, Caterina ; Wu, Wenting ; Dinca, Eduard B. ; James, C. David. / Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 3. pp. 1167-1174.
@article{340b1639926c4ac9bba96d783cd6df54,
title = "Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel",
abstract = "In the current study, we examined a panel of serially passaged glioblastoma xenografts, in the context of an intracranial tumor therapy response model, to identify associations between glioblastoma molecular characteristics and tumor sensitivity to the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib. From an initial evaluation of 11 distinct glioblastoma xenografts, two erlotinib-sensitive tumors were identified, each having amplified EGFR and expressing wild-type PTEN. One of these tumors expressed truncated EGFRvIII, whereas the other expressed full-length EGFR. Subsequent cDNA sequence analysis revealed the latter tumor as expressing an EGFR sequence variant with arginine, rather than leucine, at amino acid position 62; this was the only EGFR sequence variant identified among the 11 xenografts, other than the aforementioned vIII sequence variant. EGFR cDNAs were then examined from 12 more xenografts to determine whether additional missense sequence alterations were evident, and this analysis revealed one such case, expressing threonine, rather than alanine, at amino acid position 289 of the extracellular domain. This glioblastoma was also amplified for EGFR, but did not display significant erlotinib sensitivity, presumably due to its lacking PTEN expression. In total, our study identified two erlotinib-sensitive glioblastoma xenografts, with the common molecular characteristics shared by each being the expression of wild-type PTEN in combination with the expression of amplified and aberrant EGFR.",
author = "Sarkaria, {Jann N} and Lin Yang and Grogan, {Patrick T.} and Kitange, {Gaspar J.} and Carlson, {Brett L.} and Schroeder, {Mark A.} and Evanthia Galanis and Caterina Giannini and Wenting Wu and Dinca, {Eduard B.} and James, {C. David}",
year = "2007",
month = "3",
doi = "10.1158/1535-7163.MCT-06-0691",
language = "English (US)",
volume = "6",
pages = "1167--1174",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel

AU - Sarkaria, Jann N

AU - Yang, Lin

AU - Grogan, Patrick T.

AU - Kitange, Gaspar J.

AU - Carlson, Brett L.

AU - Schroeder, Mark A.

AU - Galanis, Evanthia

AU - Giannini, Caterina

AU - Wu, Wenting

AU - Dinca, Eduard B.

AU - James, C. David

PY - 2007/3

Y1 - 2007/3

N2 - In the current study, we examined a panel of serially passaged glioblastoma xenografts, in the context of an intracranial tumor therapy response model, to identify associations between glioblastoma molecular characteristics and tumor sensitivity to the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib. From an initial evaluation of 11 distinct glioblastoma xenografts, two erlotinib-sensitive tumors were identified, each having amplified EGFR and expressing wild-type PTEN. One of these tumors expressed truncated EGFRvIII, whereas the other expressed full-length EGFR. Subsequent cDNA sequence analysis revealed the latter tumor as expressing an EGFR sequence variant with arginine, rather than leucine, at amino acid position 62; this was the only EGFR sequence variant identified among the 11 xenografts, other than the aforementioned vIII sequence variant. EGFR cDNAs were then examined from 12 more xenografts to determine whether additional missense sequence alterations were evident, and this analysis revealed one such case, expressing threonine, rather than alanine, at amino acid position 289 of the extracellular domain. This glioblastoma was also amplified for EGFR, but did not display significant erlotinib sensitivity, presumably due to its lacking PTEN expression. In total, our study identified two erlotinib-sensitive glioblastoma xenografts, with the common molecular characteristics shared by each being the expression of wild-type PTEN in combination with the expression of amplified and aberrant EGFR.

AB - In the current study, we examined a panel of serially passaged glioblastoma xenografts, in the context of an intracranial tumor therapy response model, to identify associations between glioblastoma molecular characteristics and tumor sensitivity to the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib. From an initial evaluation of 11 distinct glioblastoma xenografts, two erlotinib-sensitive tumors were identified, each having amplified EGFR and expressing wild-type PTEN. One of these tumors expressed truncated EGFRvIII, whereas the other expressed full-length EGFR. Subsequent cDNA sequence analysis revealed the latter tumor as expressing an EGFR sequence variant with arginine, rather than leucine, at amino acid position 62; this was the only EGFR sequence variant identified among the 11 xenografts, other than the aforementioned vIII sequence variant. EGFR cDNAs were then examined from 12 more xenografts to determine whether additional missense sequence alterations were evident, and this analysis revealed one such case, expressing threonine, rather than alanine, at amino acid position 289 of the extracellular domain. This glioblastoma was also amplified for EGFR, but did not display significant erlotinib sensitivity, presumably due to its lacking PTEN expression. In total, our study identified two erlotinib-sensitive glioblastoma xenografts, with the common molecular characteristics shared by each being the expression of wild-type PTEN in combination with the expression of amplified and aberrant EGFR.

UR - http://www.scopus.com/inward/record.url?scp=34147184365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147184365&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0691

DO - 10.1158/1535-7163.MCT-06-0691

M3 - Article

VL - 6

SP - 1167

EP - 1174

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -